SVF
Level D· Preclinical EvidenceAnimal Study

Neuroprotective Potential of Conditioned Medium from Adipose and Liver Mesenchymal Stem Cells in a Rat Model of Global Cerebral Ischemia-reperfusion Injury.

Shooshtari MK., Vastegani SM., Farbood Y., Sarkaki A., Bayati V., Nejaddehbashi F.

Animal Study on Stroke Research, published in Curr Mol Med (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Curr Mol Med (2026)
Country
Netherlands
Reported sample size
—
PMID
40357793
DOI
10.2174/0115665240351634250506164609

Abstract (original English)

Mesenchymal stem cell-derived conditioned medium (MSCCM) contains bioactive factors that provide neuroprotection in cases of cerebral ischemia-reperfusion (IR) injury. This study aimed to compare the therapeutic potential of rat adipose-derived MSC-CM (rAD-MSC-CM) and chicken embryo liver-derived MSC-CM (cLD-MSC-CM) following global cerebral IR injury in male rats. We harvested rAD-MSC-CM from the adipose tissue surrounding the epididymis of Wistar rats and cLD-MSC-CM from the liver tissue of 10- day-old chicken embryos. To induce global cerebral ischemia, we utilized a four-vessel occlusion (4VO) model in rats. After inducing ischemia, the conditioned media were administered via intravenous injection 30 minutes post-reperfusion. We evaluated the cognitive and non-cognitive functions of the animals using standard behavioral tests. Additionally, we assessed blood-brain barrier (BBB) permeability, brain water content (BWC), oxidative-antioxidative status, and conducted histopathological analyses of the hippocampal tissue in the IR rats. Our findings demonstrated that treatment with both rADMSC- CM and cLD-MSC-CM significantly improved memory function, reduced anxietyand depression-like behaviors, and enhanced exploratory activities. These behavioral improvements correlated with decreased BBB permeability and BWC, reduced oxidative stress, and mitigated histopathological changes i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsReperfusion InjuryCulture Media, ConditionedMesenchymal Stem CellsMaleRatsLiverAdipose TissueBrain IschemiaDisease Models, Animal
HipSystemic / IVStroke Research
View on PubMedDOI

Related research